Latest Business and People News
Updated employee announcements, business news, awards, and recognition in the industry today.
People News
Synteract, a full-service CRO, has added two new members, Lisa Dilworth as Vice President, Rare and Orphan Diseases, and Elisabeth Schrader as Executive Director, Program Strategy, Pediatrics and Rare Diseases, to its Rare and Orphan Diseases Center of Development.
Elligo Health Research, an integrated research organization, has added Dan Pucci, MBA, as Vice President of Strategic Partnerships, and Michael A. Ibara, Pharm.D., as Vice President of Data Sciences, to its executive leadership team.
Richard Davies
Suzanne Lukac
CluePoints, a provider of RBM and data quality oversight solutions for clinical trials, has announced the appointment of Richard Davies as VP, Solutions Expert, and Suzanne Lukac as Senior Account Director to its senior team.
The International Biomedical Research Alliance, a non-profit organization that provides programming and funding support for the National Institutes of Health (NIH) Oxford-Cambridge Scholars Program, announced that Ralph A. Korpman, MD, is joining the Alliance’s Board of Directors.
Kristen Scannell
The Patient Experience Project (PEP), an EVERSANA™ agency, has announced the addition of Kristen Scannell as a Patient Experience Coordinator.
Data Cubed, a healthcare technology company, hired David Kiger, as Chief Commercial Officer to expand gamification, human, and virtual clinical trial solutions.
Business News
MMS, a global data-focused CRO, announced a volunteer initiative to pledge more than $250,000 in employee hours to local volunteer initiatives. The program allows colleagues to choose which organizations they want to support.
Medidata announced that more than 15,000 studies have been conducted on the Medidata Cloud, its platform for life sciences.
This year at CDISC Interchanges, where attendees are the first to hear about a number of new initiatives for CDISC, the standards organization updated its audience on its strategic plan priorities and revealed the new look, messaging, website, and multimedia tools of CDISC’s new brand.
Recognition
MMS Holdings Inc., a data-focused CRO, announced their support to Paratek Pharmaceuticals, Inc. for the new drug application approval and successful marketing authorization application filing of NUZYRA™ for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections.
Gartner Inc., a research and advisory company, named Data Cubed as one of the “Cool Companies” in Data-Driven Health Platforms.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
